Ilepatril
Ilepatril, a dual inhibitor of angiotensin-converting enzyme (ACE) and neutral endopeptidase, has inhibitory effects in the type 2 diabetic nephropathy model in obese Zucker diabetic fatty (ZDF) rats. Ilepatril significantly reduced albuminuria in a dose-dependent manner and may be a strategy distinct from metabolic control to inhibit type 2 diabetic nephropathy[1].
Product Specifications
CAS Number
473289-62-2
Product Name Alternative
AVE 7688
UNSPSC
12352005
Target
Angiotensin-converting Enzyme (ACE)
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/ilepatril.html
Smiles
O=C([C@@H]1CCC[C@]2([H])C3=CC=CC=C3C[C@H](NC([C@@H](SC(C)=O)C(C)C)=O)C(N21)=O)O
Molecular Formula
C22H28N2O5S
Molecular Weight
432.53
References & Citations
[1]The vasopeptidase inhibitor AVE7688 ameliorates Type 2 diabetic nephropathy
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 3
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Cytokeratin 10 (KRT10/844), CF640R conjugate, 0.1mg/mL
Double Stranded DNA (dsDNA) (121-3), Biotin conjugate, 0.1mg/mL
